Business
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607. These data are being presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 8 – 12th in Boston. “We are particularly encouraged by these initial biomarker data from the Phase 1 trial of NX-1607 measured in patients with advanced malignancies, which demonstrate remarkable concordance with levels observed in preclinical studies that are associated with potent anti-tumor activity,” said Robert J. Brown, M.D., Nurix’s executive vice president of clinical development. “The proximal biomarker of CBL-B inhibition in activated T cells can be measured in whole blood and demonstrate dose-dependence in our clinical studies enabling us to assess target engagement in the clinic and guide our selection of an appropriate dose for further expansion of the trial.” Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, added, \"Our multiple presentations at SITC illustrate the progress we have made in the development of our first-in-class CBL-B inhibitors. Of particular importance is the work we have done to identify, validate, and clinically implement assays of a key proximal biomarker of CBL-B inhibition which has enabled the first-in-human testing of NX-1607 and its novel mechanism of action. We look forward to providing additional clinical updates for NX-1607 in 2023.” Summary of data presented at the SITC Annual Meeting:NX-1607 Program Title: Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies Nurix has identified and characterized novel proximal biomarkers including phosphorylated hematopoietic lineage cell-specific protein 1...